Eversept Partners LP Has $2.24 Million Position in Sutro Biopharma, Inc. $STRO

Eversept Partners LP cut its stake in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 91.6% during the 4th quarter, HoldingsChannel reports. The firm owned 193,571 shares of the company’s stock after selling 2,097,742 shares during the period. Eversept Partners LP’s holdings in Sutro Biopharma were worth $2,240,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in Sutro Biopharma in the fourth quarter valued at approximately $265,000. Bridgeway Capital Management LLC boosted its position in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after buying an additional 30,000 shares in the last quarter. Bank of America Corp DE boosted its position in Sutro Biopharma by 51.3% in the third quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock valued at $104,000 after buying an additional 40,488 shares in the last quarter. Shay Capital LLC boosted its position in Sutro Biopharma by 20.1% in the third quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock valued at $271,000 after buying an additional 52,162 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after buying an additional 53,390 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma Price Performance

STRO opened at $28.41 on Thursday. Sutro Biopharma, Inc. has a fifty-two week low of $6.74 and a fifty-two week high of $43.85. The firm has a market capitalization of $470.75 million, a price-to-earnings ratio of -2.57 and a beta of 1.54. The company’s 50 day moving average price is $31.30 and its two-hundred day moving average price is $21.39.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The business had revenue of $14.52 million for the quarter, compared to analysts’ expectations of $8.89 million. As a group, equities research analysts predict that Sutro Biopharma, Inc. will post -9.29 EPS for the current year.

Analysts Set New Price Targets

STRO has been the topic of a number of research analyst reports. Leerink Partners set a $43.00 target price on shares of Sutro Biopharma and gave the company an “outperform” rating in a research report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Friday, May 8th. Wall Street Zen lowered shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday. Citigroup restated an “outperform” rating on shares of Sutro Biopharma in a research report on Friday, April 17th. Finally, Barclays assumed coverage on shares of Sutro Biopharma in a report on Thursday, May 28th. They set an “overweight” rating and a $56.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Sutro Biopharma presently has a consensus rating of “Moderate Buy” and an average target price of $52.44.

Sutro Biopharma Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.